Zuellig Pharma Announces Agreement with Regeneron to Introduce Libtayo®

Overview

Zuellig Pharma has entered into an exclusive distribution agreement with Regeneron Ireland DAC, a subsidiary of Regeneron Pharmaceuticals, Inc. 

About Libtayo®

• Libtayo® was developed using Regeneron's VelocImmune® technology and has received regulatory approval in over 24 countries for various medical conditions. 
• In Taiwan, it is approved for monotherapy in advanced NSCLC.

Launch & commercialization of Libtayo

This partnership will see Zuellig Pharma launch and commercialise Libtayo® (cemiplimab), a fully human monoclonal antibody that targets the PD-1 receptor on T cells, in South Korea and Taiwan.

About Regeneron

Regeneron is a leading biotechnology firm known for developing and marketing life-changing medicines for serious illnesses. 

About Libtayo

In South Korea, Libtayo® is already approved as a first-line monotherapy for advanced non-small cell lung cancer (NSCLC), as well as for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and recurrent or metastatic cervical cancer. 

Zuellig Pharma are eager to bring Libtayo® to patients in South Korea and Taiwan. Extensive experience in Asia’s biopharma sector enables us to deliver innovative therapies to the region. 

This marks an important step in the mission to enhance healthcare access and improve patient outcomes, particularly in the growing field of oncology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!